Gibson Oncology and Purdue Research Foundation divulge new Topo1 inhibitors and MycG4 ligands
Dec. 1, 2023
Gibson Oncology LLC and Purdue Research Foundation have synthesized DNA topoisomerase I (Topo1) inhibitors and/or Myc proto-oncogene protein promoter G-quadruplex (MycG4) ligands reported to be useful for the treatment of cancer.